Monensin inhibits epidermal growth factor receptor trafficking and activation: Synergistic cytotoxicity in combination with EGFR inhibitors

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2559-2571

  Dayekh, Khalil ^a,b   Johnson Obaseki, Stephanie ^c   Corsten, Martin ^c   Villeneuve, Patrick J ^a,c   Sekhon, Harmanjatinder S ^c   Weberpals, Johanne I ^a,c   Dimitroulakos, Jim ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUINDOSTATIN; MEVINOLIN; MONENSIN; PROPIDIUM IODIDE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CELL ACTIVATION; CELL CYCLE S PHASE; CELL MIGRATION; CELL VIABILITY; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOGENESIS; MTT ASSAY; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA CELL; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; ENZYMOLOGY; HEAD AND NECK NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG SYNERGISM; ERLOTINIB HYDROCHLORIDE; HEAD AND NECK NEOPLASMS; HUMANS; MONENSIN; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84919393755     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-1086     Document Type: Article

References (47)

1. Zhang Q, Bhola NE, Lui V.W., Siwak DR, Thomas SM, Gubish CT, et al Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007; 6: 1414-24.
2. Khuri FR, Kim ES, Lee J.J., Winn RJ, Benner SE, Lippman SM, et al The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001; 10: 823-9.
3. Cohen EE, Lingen MW, Vokes EE The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22: 1743-52.
4. Psyrri A, Kwong M, DiStasio S., Lekakis L, Kassar M, Sasaki C., et al. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 2004; 22: 3061-9.
5. Grandis JR, Tweardy DJ Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-84.
6. Kalyankrishna S, Grandis JR Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-72.
7. Ang KK, Berkey BA, Tu X, Zhang H.Z., Katz R., Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.
8. Chung CH, Ely K, McGavran L., Varella-Garcia M, Parker J, Parker N., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-6.
9. Salomon DS, Brandt R, Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
10. Erjala K, Sundvall M, Junttila T.T., Zhang N., Savisalo M, Mali P, et al Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006; 12: 4103-11.
11. Nozawa H, Tadakuma T, Ono T., Sato M, Hiroi S, Masumoto K., et al. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 2006; 97: 1115-24.
12. Seethala RR, Gooding WE, Handler P.N., Collins B., Zhang Q, Siegfried JM, et al Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res 2008; 14:1303-9.
13. Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003; 30: 34-46.
14. Lee CK, Brown C, Gralla R.J., Hirsh V., Thongprasert S, Tsai CM, et al Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013; 105:595-605.
15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S., Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
16. Paez JG, Janne PA, Lee J.C., Tracy S., Greulich H, Gabriel S, et al EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
17. Pressman BC. Ionophorous antibiotics as models for biological transport. Federation Proc 1968; 27: 1283-8.
18. Pressman BC. Biological applications of ionophores. Annu Rev Bio-chem 1976; 45: 501-30.
19. Park WH, Jung CW, Park J.O., Kim K., Kim WS, Im YH, et al. Monensin inhibits the growth of renal cell carcinoma cells via cell-cycle arrest or apoptosis. Int J Oncol 2003; 22: 855-60.
20. Park WH, Kim ES, Jung C.W., Kim BK, Lee YY. Monensin-mediated growth inhibition of SNU-C1 colon cancer cells via cell-cycle arrest and apoptosis. Int J Oncol 2003; 22: 377-82.
21. Park WH, Kim ES, Kim B.K., Lee YY. Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell-cycle arrest and apo-ptosis. Int J Oncol 2003; 23: 197-204.
22. Park WH, Seol JG, Kim E.S., Kang WK, Im YH, Jung CW, et al Monensin-mediated growth inhibition in human lymphoma cells through cell-cycle arrest and apoptosis. Br J Haematol 2002; 119: 400-7.
23. Ketola K, Vainio P, Fey V., Kallioniemi O, Iljin K. Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol Cancer Ther 2010; 9: 3175-85.
24. Corsini A, Maggi FM, Catapano AL Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31: 9-27.
25. Dimitroulakos J, Nohynek D, Backway K.L., Hedley DW, Yeger H, Freedman MH, et al Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999; 93: 1308-18.
26. Dimitroulakos J, Ye LY, Benzaquen M, Moore M.J., Kamel-Reid S, Freedman MH, et al Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001; 7: 158-67.
27. Dimitroulakos J, Yeger H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 1996; 2: 326-33.
28. Knox JJ, Siu LL, Chen E, Dimitroulakos J., Kamel-Reid S, Moore MJ, et al A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005; 41: 523-30.
29. Mantha AJ, Hanson JE, Goss G, Lagarde A.E., Lorimer IA, Dimitroulakos J. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 2005; 11: 2398-407.
30. Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury P.A., Dimitroulakos J. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene 2010; 29: 4682-92.
31. Zhao TT, Trinh D, Addison C.L., Dimitroulakos J. Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors. PloS ONE 2010; 5:e12563.
32. van Kuppeveld F.J., Johansson KE, Galama J.M., Kissing J., Bolske G, van der Logt JT, et al. Detection of mycoplasma contamination in cell cultures by a mycoplasma group-specific PCR. Appl Environ Microbiol 1994; 60: 149-52.
33. Wermuth CG. Selective optimization of side activities: another way for drug discovery. J Med Chem 2004; 47: 1303-14.
34. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440-6.
35. Niknejad N, Gorn-Hondermann I, Ma L., Zahr S, Johnson-Obeseki S, Corsten M, et al Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salu-brinal. Int J Cancer 2013; 134: 268-79.
36. Niknejad N, Morley M, Dimitroulakos J. Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chemistry 2007; 282: 29748-56.
37. Gladhaug IP, Christoffersen T. Rapid constitutive internalization and externalization of epidermal growth factor receptors in isolated rat hepatocytes. Monensin inhibits receptor externalization and reduces the capacity for continued endocytosis of epidermal growth factor. J Biol Chemistry 1988; 263: 12199-203.
38. Rush JS, Quinalty LM, Engelman L, Sherry D.M., Ceresa BP. Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J Biol Chemistry 2012; 287: 712-22.
39. Sorkin A, Duex JE Quantitative analysis of endocytosis and turnover of epidermal growth factor (EGF) and EGF receptor. Curr Protoc Cell Biol 2010; Chapter 15: Unit 15 4.
40. Costa V, Angelini C, De Feis I, Ciccodicola A. Uncovering the complexity of transcriptomes with RNA-Seq. J Biomed Biotechnol 2010; 2010:853916.
41. Goldstein JL, Anderson RG, Brown MS Receptor-mediated endocy-tosis and the cellular uptake of low-density lipoprotein. Ciba Foundation Symp 1982:77-95.
42. Burton TR, Gibson SB The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death. Cell Death Differ 2009; 16: 515-23.
43. Pierotti MA, Berrino F, Gariboldi M., Melani C, Mogavero A, Negri T., et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multifaceted effects. Oncogene 2013; 32:1475-87.
44. Mollenhauer HH, Morre DJ, Rowe LD Alteration of intracellular traffic by monensin; mechanism, specificity, and relationship to toxicity. Biochim Biophys Acta 1990; 1031: 225-46.
45. Tartakoff AM. Perturbation of vesicular traffic with the carboxylic ionophore monensin. Cell 1983; 32: 1026-8.
46. Choi HS, Jeong EH, Lee T.G., Kim SY, Kim HR, Kim CH. Autophagy inhibition with monensin enhances cell-cycle arrest and apoptosis induced by mTOR or epidermal growth factor receptor inhibitors in lung cancer cells. Tuberc Respir Dis 2013; 75: 9-17.
47. Aung HH, Lame MW, Gohil K, An C.I., Wilson DW, Rutledge JC. Induction of ATF3 gene network by triglyceride-rich lipoprotein lipol-ysis products increases vascular apoptosis and inflammation. Arter-ioscler Thromb Vasc Biol 2013; 33: 2088-96.